Loading...

Inhibrx Biosciences, Inc.

INBX•NASDAQ
HealthcareBiotechnology
$13.92
$1.03(7.99%)

Inhibrx Biosciences, Inc. (INBX) Stock Overview

Explore Inhibrx Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Revenue Growth
-88.89%
↓ 88.89%
Profit Growth
$111.39
↑ 799.19%
EPS Growth
$111.39
↑ 2326.76%
Operating Margin
-150262.00%
↓ 51.19%
ROE
1101.19%
↑ 799.19%
Dividend Yield
0.00%
Analyst Recommendations data is not available for INBXAnalyst Recommendations details for INBX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.

CEO

Mr. Mark Paul Lappe

Employees

156

Headquarters

11025 North Torrey Pines Road, La Jolla, CA

Founded

2024

Frequently Asked Questions